2024-09-26-世界卫生组织-Recommended_composition_of_influenza_virus_vaccines_for_use_in_the_2025_southern_hemisphere_influenza_season_11页_611kb

报告摘要

Summary of Recommended Influenza Vaccine Composition for 2025 Southern Hemisphere Season

The World Health Organization (WHO) recommended the composition of influenza vaccines for the 2025 southern hemisphere influenza season based on analysis of global influenza activity from February to August 2024. The recommendations aim to protect against circulating strains, with a focus on updating vaccine viruses.

Key Recommendations:

Trivalent vaccines:
- For egg-based, cell culture-based, recombinant protein-based, and nucleic acid-based vaccines, the recommended strains are:
  - A(H1N1)pdm09-like: A/Victoria/4897/2022 or A/Wisconsin/67/2022-equivalent.
  - A(H3N2)-like: A/Croatia/10136RV/2023 or A/District of Columbia/27/2023-equivalent.
  - B/Victoria lineage-like: B/Austria/1359417/2021-equivalent.
- These updates were based on genetic and antigenic characterization, showing good match with circulating viruses.
Quadrivalent vaccines:
- The B/Yamagata lineage antigen is included but with low risk of infection after March 2020; WHO suggests phasing it out to avoid unnecessary components.

Context:

In 2024, influenza activity was high globally, with A(H1N1)pdm09 and A(H3N2) predominating in various regions, but B/Victoria lineage remained the only circulating lineage. WHO consulted experts and reviewed genetic and antigenic properties to ensure vaccine effectiveness. National authorities approve and use these recommendations.

Additional Notes:

WHO advises on vaccine formulation and emphasizes considering trivalent or quadrivalent options based on regional needs.
Zoonotic influenza risks were monitored but low impact on human vaccine recommendations.

展开完整摘要